Precigen

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus across all key metrics following the full FDA approval of Papzimeos. Revenue reached $55.0M, drastically exceeding the $27.8M estimate, driven by rapid commercial adoption in the U.S. RRP market. Diluted EPS of $0.05 notably outperformed the expected -$0.01 loss, marking the company's first quarter of profitability since its 2020 transformation. Management highlighted that pre-launch inventory will likely be exhausted by Q3 FY26, with long-term gross margins expected to stabilize in the high 80% to low 90% range.